| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 09/12/2006 | US7105506 For therapy of cardiovascular disorders and erectile dysfunction |
| 09/12/2006 | US7105483 Phosphinic pseudopeptide derivatives for the selective inhibition of the C-terminal active site of angiotensin I converting enzyme (ACE) |
| 09/12/2006 | US7105229 Dispersing a matrix of nanostructured liquid phase or a dehydrated variant and a nanostructured liquid crystalline phase or a dehydrated variant in nonlamellar material; cooling or evaporating a volatile solvent |
| 09/12/2006 | US7105167 Administering variants of insulin-like growth factor I to treat hyperglycemic disorder, congestive heart failure, urogenital disorders, poor nutrition, or a wasting syndrome |
| 09/12/2006 | CA2312545C Solid, thermoformable, controlled-release pharmaceutical compound |
| 09/12/2006 | CA2236598C Treatment of cardiomyopathy by removal of autoantibodies |
| 09/12/2006 | CA2235986C Inhibitors of protein isoprenyl transferases |
| 09/12/2006 | CA2180730C Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation |
| 09/12/2006 | CA2167004C Agent for treating mental disorders associated with cerebrovascular disorders |
| 09/08/2006 | WO2006094248A1 Aryl-substituted cyclic sirtuin modulators |
| 09/08/2006 | WO2006094034A1 Cinnoline compounds and their use as liver x receptor modilators |
| 09/08/2006 | WO2006093823A1 2- [ isoquinolin-s - carbonyl ) amino] -propionic acid derivatives as inhibitors of factors xi and ix for the treatment of thrombosis |
| 09/08/2006 | WO2006093339A1 Use of cinnamoyl compound |
| 09/08/2006 | WO2006093336A1 Use of cinnamoyl compound |
| 09/08/2006 | WO2006093277A1 Soybean transformant having functional peptide therein and use of the same |
| 09/08/2006 | WO2006093276A1 Pluripotent stem cell derived from cardiac tissue |
| 09/08/2006 | WO2006093253A1 Novel cyclic compound having quinolylalkylthio group |
| 09/08/2006 | WO2006093205A1 Method and device for cell preparation |
| 09/08/2006 | WO2006093166A1 Enzyme-treated product comprising rice peptide and composition for improving physiological activity comprising the product |
| 09/08/2006 | WO2006093114A1 Method of producing chlorogenic acid composition |
| 09/08/2006 | WO2006093110A1 Nitroguanosine-3’,5’-cyclic monophosphate and protein kinase g activator |
| 09/08/2006 | WO2006093041A1 Novel crystals of n-benzyl-n-ethyl-2-(7-methyl-8-oxo-2-phenyl-7,8-dihydro-9h-purin-9-yl)acetoamide |
| 09/08/2006 | WO2006093013A1 Serum cholesterol-reducing agent, process for production of the same, and food composition and pharmaceutical composition having serum cholesterol-reducing effect |
| 09/08/2006 | WO2006092494A1 $g(g)d crystalline form of ivabradine hydrochloride, preparation method thereof and pharmaceutical compositions containing same |
| 09/08/2006 | WO2006092491A1 $g(b)d crystalline form of ivabradine hydrochloride, preparation method thereof and pharmaceutical compositions containing same |
| 09/08/2006 | WO2006092294A1 Folic acid-, vitamin b6- and vitamin b12-containing agents and the use thereof |
| 09/08/2006 | WO2006092209A1 Novel targets and compounds useful in the treatment of a cardiovascular disorder, dyslipidemia and atherosclerosis, and methods to identify such compounds |
| 09/08/2006 | WO2006092025A1 Compounds having lipid lowering properties |
| 09/08/2006 | WO2006071548A3 Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases |
| 09/08/2006 | WO2006063811A3 Substituted 1,2,4-triazin-5(2h)-ones |
| 09/08/2006 | WO2006051502A3 Sulfamides as endothelin receptor antagonists for the treatment of cardiovascular diseases |
| 09/08/2006 | WO2006044596A3 Multi-domain amphipathic helical peptides and methods of their use |
| 09/08/2006 | WO2006030306A3 Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder |
| 09/08/2006 | WO2006008091A3 Oxidative degradation products of atorvastatin calcium |
| 09/08/2006 | WO2006006080A3 Sodium channel agonist |
| 09/08/2006 | WO2003028696A8 Compositions for delivery of drug combinations |
| 09/08/2006 | CA2600653A1 Pluripotent stem cell derived from cardiac tissue |
| 09/08/2006 | CA2600287A1 Use of cinnamoyl compound |
| 09/08/2006 | CA2599808A1 2- [ isoquinolin-s - carbonyl ) amino] -propionic acid derivatives as inhibitors of factors xi and ix for the treatment of thrombosis |
| 09/08/2006 | CA2599712A1 Folic acid-, vitamin b6- and vitamin b12-containing agents and the use thereof |
| 09/08/2006 | CA2599688A1 Cinnoline compounds and their use as liver x receptor modulators |
| 09/08/2006 | CA2599612A1 Use of phosphate derivatives of electron transfer agents for lowering increased circulating blood levels of a lipid |
| 09/07/2006 | US20060199962 1-Methoxy-3-(3-methoxy-4-nitrobenzoyl)-2-methylindolizin-6-yl]carboxamide; angiogenesis inhibitors; antitumor, -carcinogenic, and metastasis agent; rheumatic diseases; antiarthritic agents; atherosclerosis; retenosis; leukemia; cardiotonic agents; imflammatory bowel disease; obesity; antidiabetic agents |
| 09/07/2006 | US20060199957 Novel bicyclic and tricyclic cannabinoids |
| 09/07/2006 | US20060199861 Methods of using derivatives of (-)-venlafaxine |
| 09/07/2006 | US20060199860 Salts of (-)-O-desmethylvenlafaxine |
| 09/07/2006 | US20060199859 Topical medicaments and methods for photodynamic treatment of disease |
| 09/07/2006 | US20060199827 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 09/07/2006 | US20060199825 4-Aminating a 4-chloro-2-hydroxy-3-nitrodihydroquinoline with a N-(hetero)cyclylpiperazine, and alkylating the remaining amine group in the quinoline ring to produce a 4-(4-(hetero)cyclylpiperazinyl)-3-nitro-1-alkyldihydroquinolinone |
| 09/07/2006 | US20060199820 e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma |
| 09/07/2006 | US20060199819 Inhibition of cyclooxygenase-2 activity |
| 09/07/2006 | US20060199818 Inhibiting the activity of a 5-hydroxytryptamine 2A by administering a N-heterocyclyl (preferably 1,3-dioxan-5-yl)-4-[(N-substituted)(hetero)arylamino]piperidine in which the N-substituant is arylalkanoyl, arylthioalkanoyl, arylalkylaminocarbonyl or arylalkylaminothiocarbonyl group |
| 09/07/2006 | US20060199815 NK1 antagonists |
| 09/07/2006 | US20060199795 e.g. 2-[3,5-trans-5-(3-aminophenyl)-7-chloro-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-N-(2-fluorobenzyl)acetamide; G-protein-coupled receptor (TGR5) agonist; central nervous system diseases; antiinflammatory agent; learning enhancement; angina pectoris, arrhythmia, bronchial asthma |
| 09/07/2006 | US20060199794 avoid the adverse side effects associated with non-selective receptor interactions; 1-(4-Fluorobenzyl)-2-(4-methoxybenzyl)-8-methyl-1,2,8-triaza-spiro[4.5]decan-3-one; 1-oxa-4,9-diaza-spiro[5.5]undecan-3-one compounds as monoamine receptor modulators; schizophrenia, psychosis, migraine, hypertension |
| 09/07/2006 | US20060199793 Sterol absorption inhibitor compounds |
| 09/07/2006 | US20060199792 Peroxynitrite decomposition catalysts and methods of use thereof |
| 09/07/2006 | US20060199787 N-(2-acetamidoethyl)phosphonoformamide; inhibiting effect on zinc-containing proteinases, inhibiting cancer cells |
| 09/07/2006 | US20060199772 Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy |
| 09/07/2006 | US20060199767 Contacting cardiac muscle cells with a neuregulin protein to activate the MAP kinase pathway in cardiac muscle cells and induce remodeling of cardiac muscle cell sarcomeric and cytoskeleton structures or cell-cell adhesions |
| 09/07/2006 | US20060199762 Skin ulcer preventive curative agent containing human recombinant hgf |
| 09/07/2006 | US20060198846 Combinations for the treatment of diseases involving angiogenesis |
| 09/07/2006 | US20060198831 Nitrosylation of protein SH groups and amino acid residues as a therapeutic modality |
| 09/07/2006 | DE19526233B4 Hydroxylierte Azabicyclooctyl-tetra- und -hexahydrobenz[d,e]isochinolone, deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten Hydroxylated Azabicyclooctyl tetra- and -hexahydrobenz [e] isochinolone, their preparation and pharmaceutical compositions containing these |
| 09/07/2006 | DE102005009909A1 Verbindungen geeignet zur Beseitigung fehlgefalteter Proteine Compounds suitable for the removal of misfolded proteins |
| 09/07/2006 | DE102005009705A1 Use of naphthalene derivatives for the treatment of hyperaldosteronism, heart failure, myocardial fibrosis, hypercortisolism and diabetes mellitus |
| 09/07/2006 | DE102005009379A1 Mittel, enthaltend Folsäure, Vitamin B6 und Vitamin B12, und dessen Verwendung Compositions comprising folic acid, vitamin B6 and vitamin B12, and its use |
| 09/07/2006 | DE10038043B4 Phamakologisch wirksame Substanz zur Behandlung kardiovaskulärer Erkrankungen Of pharmacologically active substance for the treatment of cardiovascular diseases |
| 09/06/2006 | EP1698697A2 SSD-containing protein, process for producing the same and use thereof |
| 09/06/2006 | EP1698629A2 Polyamines and their use in therapy |
| 09/06/2006 | EP1698627A1 Pyrazole compounds useful as protein kinase inhibitors |
| 09/06/2006 | EP1698626A1 Amidopyrazole derivative |
| 09/06/2006 | EP1698624A1 Phenylpropanoic acid derivatives |
| 09/06/2006 | EP1698623A1 Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these |
| 09/06/2006 | EP1698622A1 Agent or method for treatment for severe aphasia in chronic-stage cerebrovascular disorder |
| 09/06/2006 | EP1698375A1 Azetidine ring compounds and drugs comprising the same |
| 09/06/2006 | EP1698348A1 Remedy/preventive for vascular disorders and hypertension and method of screening the same |
| 09/06/2006 | EP1698340A1 T-type calcium channel inhibitor |
| 09/06/2006 | EP1698335A1 Preventive and/or therapeutic agent for disease in which mitochondrial benzodiazepine receptor participates |
| 09/06/2006 | EP1697536A2 Novel oligonucleotides and treating cardiac disorders by using the same |
| 09/06/2006 | EP1697382A2 Rifamycin analogs and uses thereof |
| 09/06/2006 | EP1697356A1 Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors |
| 09/06/2006 | EP1697351A1 2,6-bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
| 09/06/2006 | EP1697318A1 Prolinylarylacetamides |
| 09/06/2006 | EP1696948A1 Use of relaxin as adjuvant in the differentiation of stem cells for the reconstruction of tissues |
| 09/06/2006 | EP1696924A1 Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies |
| 09/06/2006 | EP1696900A1 Use of treprostinil to treat and prevent ischemic lesions |
| 09/06/2006 | EP1562935B1 Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors |
| 09/06/2006 | EP1487836B1 Ethane-1,2-diamino-bis (2r)-2-bromo-3-phenylpropanoate|, method for production and use thereof |
| 09/06/2006 | EP1458673B1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) |
| 09/06/2006 | EP1453520B1 Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances |
| 09/06/2006 | EP1451208B1 Concentrating aqueous fractions of lisinopril by reverse osmosis |
| 09/06/2006 | EP1423357B1 Urea derivatives with antiproteolytic activity |
| 09/06/2006 | EP1420771B1 Use of trifluoroacetyl alkyl-substituted phenyl derivatives, phenol derivatives, and benzoyl derivatives in the treatment and/or prophylaxis of obesity and accompanying diseases and/or secondary diseases |
| 09/06/2006 | EP1406609B1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 09/06/2006 | EP1401464B1 Dietetic preparation with hypocholesterolemic activity |
| 09/06/2006 | EP1401441A4 Allosteric adenosine receptor modulators |
| 09/06/2006 | EP1349553B1 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain |
| 09/06/2006 | EP1345607B1 Therapeutic combination of amlodipine and benazepril / benazeprilat |
| 09/06/2006 | EP1303308B1 Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders |